Can GLP-1 Medications Help With Addiction? Alcohol, Smoking, Opioids Explained
- Joshua Silva, MD
- 4 days ago
- 5 min read
Medically authored by Joshua Silva, MD | Evidence-Based Weight Loss at Potere Health MD
Yes—early research shows GLP-1 medications like semaglutide and tirzepatide may reduce cravings and reward-driven behaviors related to alcohol and other substances. However, they are not FDA-approved for addiction, and evidence varies by substance and study type.¹
How GLP-1 Medications Affect Addiction (Brain and Dopamine Explained)
GLP-1 medications may influence addiction by modulating reward-related brain pathways involved in reinforcement and motivation. These pathways overlap with appetite regulation, which may explain why some patients experience reduced cravings for substances like alcohol or nicotine.²
What this means clinically
Appetite and addiction share overlapping neurobiology
GLP-1 signaling may reduce reinforcement from substances
Patients often describe reduced “craving” or “noise”
Important: This mechanism is supported by preclinical and emerging human data but is not yet fully established in humans.²
Do GLP-1 Medications Reduce Alcohol Cravings? (Semaglutide Evidence)
Yes—this is where the strongest human evidence exists.
A 2025 randomized clinical trial found that semaglutide reduced alcohol consumed during a laboratory drinking task, lowered peak breath alcohol levels, and reduced weekly alcohol cravings in adults with alcohol use disorder. Some—but not all—drinking outcomes improved, so larger trials are still needed.¹
Does Tirzepatide Help With Addiction? What We Know So Far
Promising—but not yet proven in clinical trials.
Tirzepatide acts on:
GLP-1 receptors
GIP receptors
This creates a strong biological rationale for influencing reward pathways. However:
Addiction-specific trials are ongoing
There is no completed high-quality human evidence yet
Clinical takeaway: Tirzepatide should be viewed as a promising candidate, not a proven treatment for addiction.⁴
Do GLP-1 Medications Help With Smoking, Nicotine, or Opioids?
Evidence is emerging but varies by substance.
Nicotine (smoking)
A small pilot randomized trial using exenatide alongside nicotine replacement therapy showed:
46.3% abstinence vs 26.8% placebo
Reduced withdrawal symptoms and weight gain³
Interpretation: Promising early evidence in a specific population (overweight/prediabetic smokers)
Opioids
Phase II trials are ongoing⁵
No definitive randomized clinical outcomes yet
Broader substance use (observational evidence)
Large VA cohort (>600,000 patients with type 2 diabetes):
~14% lower overall substance use disorder risk
Up to ~25% lower opioid use disorder risk
Lower overdose and mortality rates⁶
Important: This was an observational study in patients with diabetes, meaning it shows association—not causation—and may not apply to all populations.⁶
Are GLP-1 Medications FDA-Approved for Addiction?
No.
GLP-1 medications are not FDA-approved for addiction
Use in this context is off-label
Prescribing is typically based on metabolic indications (e.g., obesity, diabetes)
Can You Drink Alcohol on GLP-1 Medications? (Safety and Side Effects)
Alcohol is not strictly contraindicated with GLP-1 medications, but it may worsen common side effects like nausea and reflux—read our full safety guide here: Alcohol and GLP-1 Safety Guide.
Why GLP-1 Medications May Reduce Both Weight and Cravings
GLP-1 medications are designed to treat metabolic disease—but their effects may extend beyond weight.
For appropriate patients:
Primary effect: weight loss and metabolic improvement
Secondary effect: reduced reward-driven behaviors
Best interpretation: These medications do not directly treat addiction but may provide biological support that makes behavior change more achievable.
What We See in Clinical Practice
In clinical practice, some patients on semaglutide and tirzepatide report drinking less alcohol and experiencing a reduced pull toward certain reward-driven behaviors.
Some describe these changes as extending beyond food and alcohol to other behaviors they previously found difficult to control, including gambling or similar compulsive patterns.
For patients who already meet medical criteria for GLP-1 therapy and are motivated to change an addictive behavior, these medications may serve as a supportive tool—potentially making behavior change easier when combined with established approaches.
These observations are anecdotal and vary between individuals and should not be interpreted as treatment for addiction, though they are consistent with emerging research on reward pathways.
What the Evidence Shows (Quick Summary)
Area | Strength of Evidence | Key Takeaway |
Alcohol | Randomized trial | Reduced craving + some drinking outcomes¹ |
Nicotine | Pilot RCT | Promising but early evidence³ |
Opioids | Ongoing trials | Not yet established⁵ |
Broad SUD | Observational cohort | Association, not causation⁶ |
Tirzepatide | Mechanistic + trials underway | Promising, unproven⁴ |
Detailed Clinical Evidence (For Those Who Want the Data)
Study | Design | Population | Key Outcomes | Interpretation |
Hendershot 2025 | Randomized controlled trial | 48 adults with AUD | ↓ alcohol consumed, ↓ peak BAC, ↓ craving | Strongest human evidence, early phase¹ |
Yammine 2021 | Pilot RCT | Overweight/prediabetic smokers | 46.3% vs 26.8% abstinence | Promising but small, adjunct therapy³ |
VA Cohort 2026 | Observational (>600K) | Veterans with T2DM | 14–25% ↓ SUD risk | Association, not causation⁶ |
OUD Trials | Phase II ongoing | Patients with opioid use disorder | Pending | Not yet established⁵ |
GLP-1 and Addiction: Common Questions
Do GLP-1 medications treat addiction?
No. They are not approved for addiction but may reduce cravings and support behavior change.
Why do GLP-1 drugs reduce cravings?
They appear to influence reward-related pathways involved in reinforcement and motivation.
Is this effect proven?
Partially. Alcohol use disorder has randomized trial evidence; other areas rely on early or observational data.
Should GLP-1s be used for addiction alone?
No. They should be used for approved indications under medical supervision, with any addiction-related effects considered secondary.
Bottom Line: Do GLP-1 Medications Help With Addiction?
GLP-1 medications show promising early evidence for reducing alcohol cravings and may influence other reward-driven behaviors. However, they are not FDA-approved for addiction, and current evidence ranges from randomized trials (alcohol) to observational and early-stage research for other substances.
About the Author
Dr. Joshua Silva, MD, is a licensed physician and Medical Director of Potere Health MD. He earned his medical degree from the University of Hawaiʻi John A. Burns School of Medicine and completed residency training in Occupational and Environmental Medicine at the University of Utah, where he also earned a master’s degree in Occupational Health. He later completed a Master of Business Administration with an emphasis in health care administration at Ohio University.
Dr. Silva specializes in evidence-based weight management and the clinical use of GLP-1 and GIP therapies such as semaglutide and tirzepatide. His work also focuses on how these medications affect appetite regulation, reward pathways, and craving-driven behaviors, including emerging research on alcohol, nicotine, and other compulsive patterns. He provides in-person and virtual care for patients in Salt Lake City, St. George, and Cedar City, Utah.
References (AMA Style)
Hendershot CS, Stangl BL, Claus ED, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025.
https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2829811
Skibicka KP. The central GLP-1: implications for food and drug reward. Front Neurosci. 2013;7:181.
Yammine L, Green CE, Kosten TR, et al. Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain: a pilot randomized controlled trial. Nicotine Tob Res. 2021;23(10):1682-1690.
ClinicalTrials.gov. Tirzepatide for alcohol use disorder. ClinicalTrials.gov identifier: NCT06994338. Updated 2025. Accessed 2026.
ClinicalTrials.gov. GLP-1 receptor agonists in opioid use disorder (eg, NCT04199728). Accessed 2026.
Cai M, Bowe B, Xie Y, Al-Aly Z. Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study. BMJ. 2026;392:e086886.